After finishing at $26.56 in the prior trading day, Pfizer Inc. (NYSE: PFE) closed at $26.59, up 0.11%. In other words, the price has increased by $+0.03 from its previous closing price. On the day, 46122781 shares were traded. PFE stock price reached its highest trading level at $26.90 during the session, while it also had its lowest trading level at $26.51.
Ratios:
Our goal is to gain a better understanding of PFE by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.83 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 31.33. For the most recent quarter (mrq), Quick Ratio is recorded 0.69 and its Current Ratio is at 0.91. In the meantime, Its Debt-to-Equity ratio is 0.84 whereas as Long-Term Debt/Eq ratio is at 0.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on February 23, 2024, initiated with a Buy rating and assigned the stock a target price of $36.
On January 04, 2024, TD Cowen Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $32.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 when Gottlieb Scott bought 3,000 shares for $26.47 per share. The transaction valued at 79,401 led to the insider holds 9,000 shares of the business.
Gottlieb Scott bought 1,000 shares of PFE for $38,580 on May 08. The Director now owns 6,000 shares after completing the transaction at $38.58 per share. On May 05, another insider, Gottlieb Scott, who serves as the Director of the company, bought 1,000 shares for $38.42 each. As a result, the insider paid 38,425 and bolstered with 5,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PFE now has a Market Capitalization of 150.15B and an Enterprise Value of 208.30B. As of this moment, Pfizer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 73.98, and their Forward P/E ratio for the next fiscal year is 9.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.57 while its Price-to-Book (P/B) ratio in mrq is 1.69. Its current Enterprise Value per Revenue stands at 3.56 whereas that against EBITDA is 21.80.
Stock Price History:
Over the past 52 weeks, PFE has reached a high of $42.22, while it has fallen to a 52-week low of $25.76. The 50-Day Moving Average of the stock is 27.95, while the 200-Day Moving Average is calculated to be 32.62.
Shares Statistics:
The stock has traded on average 47.73M shares per day over the past 3-months and 37.88M shares per day over the last 10 days, according to various share statistics. A total of 5.65B shares are outstanding, with a floating share count of 5.64B. Insiders hold about 0.04% of the company’s shares, while institutions hold 70.11% stake in the company. Shares short for PFE as of Feb 15, 2024 were 60.68M with a Short Ratio of 1.27, compared to 57.58M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.07% and a Short% of Float of 1.07%.
Dividends & Splits
In the trailing 12 months, PFE’s forward annual dividend rate was 1.64, compared to 1.65 this year. Against a Trailing Annual Dividend Yield of 6.17%, it implies a Forward Annual Dividend Yield of 6.32%. The stock’s 5-year Average Dividend Yield is 3.92. The current Payout Ratio is 439.41% for PFE, which recently paid a dividend on Mar 01, 2024 with an ex-dividend date of Jan 25, 2024. Stock splits for the company last occurred on Nov 17, 2020 when the company split stock in a 1054:1000 ratio.
Earnings Estimates
Its stock is currently analyzed by 13 different market analysts. On average, analysts expect EPS of $0.52 for the current quarter, with a high estimate of $0.6 and a low estimate of $0.4, while EPS last year was $1.23. The consensus estimate for the next quarter is $0.45, with high estimates of $0.55 and low estimates of $0.36.
Analysts are recommending an EPS of between $2.35 and $2.05 for the fiscal current year, implying an average EPS of $2.2. EPS for the following year is $2.74, with 16 analysts recommending between $3.18 and $2.22.
Revenue Estimates
10 analysts predict $14.28B in revenue for the current quarter. It ranges from a high estimate of $14.76B to a low estimate of $13.08B. As of the current estimate, Pfizer Inc.’s year-ago sales were $16.59B, an estimated decrease of -13.90% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $13.64B, an increase of 7.10% over than the figure of -$13.90% in the same quarter last year. There is a high estimate of $17.12B for the next quarter, whereas the lowest estimate is $12.69B.
A total of 18 analysts have provided revenue estimates for PFE’s current fiscal year. The highest revenue estimate was $60.89B, while the lowest revenue estimate was $58.5B, resulting in an average revenue estimate of $59.98B. In the same quarter a year ago, actual revenue was $58.5B, up 2.50% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $62.74B in the next fiscal year. The high estimate is $64.96B and the low estimate is $61.06B. The average revenue growth estimate for next year is up 4.60% from the average revenue estimate for this year.
